Cargando…
Current Challenges in Glioblastoma: Intratumour Heterogeneity, Residual Disease, and Models to Predict Disease Recurrence
Glioblastoma (GB) is the most common primary malignant brain tumor, and despite the availability of chemotherapy and radiotherapy to combat the disease, overall survival remains low with a high incidence of tumor recurrence. Technological advances are continually improving our understanding of the d...
Autores principales: | Ellis, Hayley P., Greenslade, Mark, Powell, Ben, Spiteri, Inmaculada, Sottoriva, Andrea, Kurian, Kathreena M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4644939/ https://www.ncbi.nlm.nih.gov/pubmed/26636033 http://dx.doi.org/10.3389/fonc.2015.00251 |
Ejemplares similares
-
Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma
por: Padfield, Emily, et al.
Publicado: (2015) -
Biological Rationale for the Use of PPARγ Agonists in Glioblastoma
por: Ellis, Hayley Patricia, et al.
Publicado: (2014) -
Current Advances in Checkpoint Inhibitors: Lessons from Non-Central Nervous System Cancers and Potential for Glioblastoma
por: Lakin, Natasha, et al.
Publicado: (2017) -
Targeting the Ubiquitin System in Glioblastoma
por: Scholz, Nico, et al.
Publicado: (2020) -
Intratumour heterogeneity in microRNAs expression regulates glioblastoma metabolism
por: Alfardus, Huda, et al.
Publicado: (2021)